Department of Chemical Research, Schering-Plough Research Institute K15 2545, Kenilworth, NJ 07033, USA. jing.su@spcorp.com
Abstract:
To address the hERG liability of MCHR1 antagonists such as 1 and 2, new analogs such as 4 and 5 that incorporated a polar heteroaryl group were designed and synthesized. Biological evaluation confirmed that these new analogs retained MCH R1 activity with greatly attenuated hERG liabilities as indicated in the Rb efflux assay.